Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial
Drug Design, Development and Therapy · 2026-03 · Volume 20 · 1-12
DOI: 10.2147/dddt.s582482 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2026-03. Verfasst von Na Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, People's Republic of China. Hauptthemen laut MEDLINE: Sufentanil, Analgesics, Opioid, Thoracoscopy, Postoperative Pain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Purpose
To investigate the efficacy and safety of oliceridine for anesthesia induction, maintenance and analgesia in patients undergoing thoracoscopic lobectomy. Patients and Methods: In this single-center, prospective, double-blind, randomized controlled trial, patients scheduled for surgery between October 2024 and August 2025 were divided into two groups: oliceridine group (Group O) and sufentanil group (Group S). Study drugs were used for anesthesia induction, maintenance and postoperative analgesia. The primary outcome was the incidence of postoperative opioid-related adverse events within the first 48 hours, including PONV, respiratory depression, dizziness, pruritus, and constipation. Secondary outcomes included hemodynamic parameters, NRS and Ramsay Sedation Scale at multiple time points of post-surgery (2h, 6h, 12h, 24h, and 48h), the usage of postoperative analgesia drugs, rescue treatments, and Quality of Recovery-15 (QoR-15) scores.
Results
A total of 166 patients were enrolled (Group O: n=83, Group S: n=83). Compared to Group S, Group O showed significantly lower rates of PONV and respiratory depression (P 0.05).
Conclusion
Oliceridine provides safe and effective perioperative analgesia for patients undergoing thoracoscopic lobectomy. It maintains stable hemodynamics, achieves analgesic efficacy comparable to sufentanil, and demonstrates a superior profile in reducing opioid-related adverse events while promoting postoperative recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, People's Republic of China.
- Medical School of Yangzhou University, Yangzhou, Jiangsu, 225000, People's Republic of China.
- Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, 214000, People's Republic of China.
- Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People's Republic of China.
Zitieren
APA
Hu, N., Wang, C., Zhang, Q. Q., Zhang, Z. J., Ding, X., & Zhang, Y. (2026). Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial. Drug Design, Development and Therapy, Volume 20, 1-12. https://doi.org/10.2147/dddt.s582482
Vancouver
Hu N, Wang C, Zhang QQ, Zhang ZJ, Ding X, Zhang Y. Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial. Drug Design, Development and Therapy. 2026;Volume 20:1-12. doi:10.2147/dddt.s582482
BibTeX
@article{Hu2026,
author = {Hu, Na and Wang, Chong and Zhang, Qi-Qi and Zhang, Zhong-Jun and Ding, Xian and Zhang, Yu},
title = {Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--12},
doi = {10.2147/dddt.s582482}
}
EUVIMED